Based on Vaccines for Children (VFC) provider profile data and review of vaccine ordering history, most sites are eligible to receive nirsevimab. Ordering for VFC nirsevimab is available in the Vaccine Ordering Management System (VOMS).

The Ohio VFC program is receiving weekly top-off allocations from the Centers for Disease Control and Prevention (CDC) of both the 50mg and 100mg nirsevimab products.

Below is an estimated amount of product that will be made available to Ohio for VFC providers each week. Please note that Ohio's threshold from CDC is replenished at the amount that was ordered. For example, if 1,000 total doses of 50mg nirsevimab are ordered the previous week, Ohio will have the 1,000 doses of 50mg nirsevimab replenished in the next top-off.

50mg Nirsevimab Doses.

• Top-off occurring on week beginning with - number of 50mg doses available.
  • 11/12/2024* - 3,110.
  • 11/18/2024 - 3,110.
  • 11/25/2024 - 3,110.
  • 12/9/2024 - 4,670.
  • 12/23/2024 - 4,670.
  • 1/6/2025 - 4,670.
  • 1/20/2025 - 4,670.
  • 2/3/2025 - 4,670.
  • 2/17/2025 - 4,670.

100mg Nirsevimab Doses.

• Top-off occurring on week beginning with - number of 100mg doses available.
  • 11/12/2024* - 2,040.
  • 11/18/2024 - 2,040.
  • 11/25/2024 - 2,040.
  • 12/9/2024 - 510.
  • 12/23/2024 - 510.
  • 1/6/2025 - 510.
  • 1/20/2025 - 510.
  • 2/3/2025 - 510.
  • 2/17/2025 - 510.

*Occurring on a Tuesday due to Monday Veteran's Day holiday

VFC providers are encouraged to order these products for administration to eligible patients while the products remain available.

Nirsevimab Administration Recommendations

1. Administer to all infants less than 8 months of age, born during or entering their first RSV season (typically starting October 1 through March 31 in most of the continental U.S.).
   • Infants born shortly before or during the RSV season should receive nirsevimab within one week of birth.
   • Only a single dose of nirsevimab is recommended for the infant's first RSV season. The infant's weight is used to determine the appropriate dose.
2. Administer to children ages 8 to 19 months¹ who remain vulnerable to severe RSV disease when entering their second RSV season.

Nirsevimab Product Information

• Beyfortus 50mg.
  • VOMS Order Set: VFC RSV.
  • Weight Indication: Under 5 kg (under 11 lbs.).
  • Presentation: Single dose vial; 5 pack.
  • Minimum Order Quantity: 5 doses.

• Beyfortus 100mg.
  • VOMS Order Set: VFC RSV.
  • Weight Indication: 5+ kg (11+ lbs.) and over.
  • Presentation: Single dose vial; 5 pack.
  • Minimum Order Quantity: 5 doses.

Nirsevimab has been shown to be extremely effective at reducing severe symptoms from RSV. The ODH VFC Program encourages you to order VFC products and assure parents/guardians of patients are educated on the importance of nirsevimab in protecting their infants against RSV.

If you have any questions, reach out to the Immunization Program at 1-800-282-0546.

1. Nirsevimab: Eight- to 19-Month-Old Eligibility Criteria.

• Children with chronic lung disease of prematurity who required medical support during the six months (diuretics, oxygen, chronic steroids) before the start of the second RSV season.
• Children who are severely immunocompromised.
• Children with cystic fibrosis who have manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) or have weight-for-length that is less than 10th percentile.
• American Indian and Alaska Native children (note that this is a new group for whom second-season prophylaxis is recommended in contrast to the current palivizumab recommendations).

Public link

Please use the above public link if you want to share this noodl on another website.